Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as Small Cell Lung Cancer (SCLC). The study is evaluating a new treatment called Ifinatamab deruxtecan, also known by its code name DS-7300a. This treatment is a special kind of medicine called an antibody-drug conjugate (ADC), which is designed to target cancer cells more precisely. The trial will compare the effectiveness of Ifinatamab deruxtecan with standard chemotherapy treatments, such as Topotecan, in patients whose cancer has returned after initial treatment.

The purpose of the study is to see how well Ifinatamab deruxtecan works compared to chemotherapy in treating SCLC. Participants in the study will receive either Ifinatamab deruxtecan or a treatment chosen by their doctor, which may include Topotecan or other chemotherapy options. The study will monitor how the cancer responds to the treatment and how long patients live after starting the treatment. This will help researchers understand if the new treatment is more effective than the current options.

Participants will receive their assigned treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of time, during which patients will have regular check-ups to monitor their health and the progress of their cancer. The trial aims to provide valuable information that could lead to better treatment options for people with relapsed SCLC in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Sign and date the informed consent form. This is necessary before any study-specific procedures can begin.

    Ensure eligibility by meeting criteria such as being an adult, having documented small cell lung cancer (SCLC), and having received prior therapy with a platinum-based treatment.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either the study drug ifinatamab deruxtecan or a treatment chosen by the physician.

  3. Step 3

    Treatment administration

    Receive ifinatamab deruxtecan as an intravenous infusion. The frequency and dosage will be determined by the study protocol.

    Alternatively, if assigned to the physician's choice group, receive topotecan as an intravenous infusion, following the physician's prescribed schedule.

  4. Step 4

    Monitoring and assessments

    Undergo regular assessments to monitor the response to treatment. This includes measuring tumor size and checking for any side effects.

    Assessments will be conducted by both the study team and an independent review to ensure accuracy.

  5. Step 5

    Follow-up

    Continue to be monitored for overall survival and any long-term effects of the treatment.

    The study aims to compare the effectiveness of ifinatamab deruxtecan with standard chemotherapy in terms of response rate and survival.

Who can join the trial?

9 criteria

  • Sign and date the informed consent form before starting any study-specific procedures.
  • Be an adult, which means being at least 18 years old or the minimum legal adult age, whichever is higher, at the time of signing the informed consent form.
  • Have a confirmed diagnosis of Small Cell Lung Cancer (SCLC) through specific medical tests.
  • Provide a sample of the tumor that is of good quality and enough quantity for the study.
  • Have received only one previous treatment with a type of medication called platinum-based therapy for SCLC, with at least two cycles of treatment and a break from chemotherapy of at least 30 days.
  • Have at least one tumor that can be measured according to specific guidelines called RECIST v1.1, as determined by the study doctor.
  • Have proof of the disease getting worse on or after the most recent treatment.
  • Have an ECOG Performance Status of 0 or 1, which is a scale used to assess how well a person can perform daily activities.
  • Can have brain metastases (cancer spread to the brain) if they are untreated and not causing symptoms, or if they have been treated and are no longer causing symptoms, and do not need treatment with steroids or anticonvulsants, as long as they have recovered from any immediate side effects of radiation therapy.

Who cannot join the trial?

4 criteria

  • Patients who have a different type of cancer other than Small Cell Lung Cancer (SCLC) cannot participate. SCLC is a specific type of lung cancer.
  • Patients who are not within the specified age range for the study cannot participate. The study has specific age requirements.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.
  • Patients who do not meet the gender requirements of the study cannot participate. The study includes both male and female participants.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ifinatamab Deruxtecan (I-DXd) is a medication being studied for its effectiveness in treating small cell lung cancer (SCLC). It is a type of drug known as an antibody-drug conjugate, which means it combines an antibody with a chemotherapy drug. The antibody part helps the medication find and attach to cancer cells, while the chemotherapy part works to kill the cancer cells. This study aims to see how well I-DXd works compared to other chemotherapy treatments chosen by doctors for patients whose cancer has returned after previous treatments.

What is already known about the treatment

Ifinatamab Deruxtecan – This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating small cell lung cancer (SCLC). It is a B7-H3 antibody-drug conjugate, which means it targets specific proteins on cancer cells to deliver a toxic drug directly to them, aiming to kill the cancer cells while sparing healthy ones. The main therapeutic indication for Ifinatamab Deruxtecan is relapsed SCLC, and it is classified pharmacologically as an antibody-drug conjugate. The medication is still under investigation, and its effectiveness is being compared to standard chemotherapy treatments in ongoing studies.

Investigated diseases

Small Cell Lung Cancer (SCLC) – This is a fast-growing type of lung cancer that primarily affects smokers. It is characterized by small cells that multiply quickly and form large tumors. SCLC often starts in the bronchi, which are the main airways of the lungs, and can spread rapidly to other parts of the body, including the lymph nodes, liver, bones, and brain. The disease is typically divided into two stages: limited stage, where cancer is confined to one lung and nearby lymph nodes, and extensive stage, where it has spread more widely. Symptoms may include coughing, chest pain, shortness of breath, and weight loss. Due to its aggressive nature, SCLC is often diagnosed at an advanced stage.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-509628-16-00Protocol codeDS7300-188Estimated enrolment576 patientsSponsorDaiichi Sankyo Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.